Abstract Human ageing is accompanied with deterioration in endocrine functions the most notable and well characterized of which being the decrease in the production of sex hormones. Current research literature suggests that low sex hormone concentration may be among the key mechanism for sarcopenia and muscle weakness. Within the European large scale MYOAGE project, the role of sex hormones, estrogens and testosterone, in causing the aging-related loss of muscle mass and function was further investigated. Hormone replacement therapy (HRT) in women is shown to diminish age-associated muscle loss, loss in fast muscle function (power), and accumulation of fat in skeletal muscle. Further HRT raises the protein synthesis rate in skeletal muscle after resistance training, and has an anabolic effect upon connective tissue in both skeletal muscle and tendon, which influences matrix structure and mechanical properties.
Introduction
Human ageing is accompanied by deterioration in endocrine functions resulting in decreased concentrations of circulating hormones. As hormones have a key regulatory role in the metabolism of different tissues, age-induced changes in the endocrine system have notable effects on the functions of different organs and body systems as well as on functional capacity and health among middle-aged and older people. During normal ageing, the most notable and well characterized change in hormonal systems is the decrease in sex hormone production. Current research literature suggests that low sex hormone concentrations are among the key mechanisms for sarcopenia and age-induced decrease in muscle strength and power. However, the underlying biological mechanisms by which ageinduced sex hormone deprivation affects muscle mass and function are largely unknown.
A large scale integrative research project MYO-AGE was designed to increase understanding on aging related muscle weakness and the strategies by which muscle mass and strength decline by aging could be attenuated. With the unique combination of expertise in the project, the role of estrogens and testosterone in skeletal muscle structure, composition and function among middle-aged and older men and women was also investigated. A large part of the research endeavours concentrated on exploring the biological mechanisms that could explain the observed adaptations of skeletal muscle to postmenopausal estrogencontaining hormone replacement therapy (HRT). This review article summarizes the sex hormones related results of the MYOAGE project which were published before the end of 2012.
Sex hormones and ageing

Menopause in women
Menopause is defined as the final menstrual period. The mean menopausal age is 51 years. As the lifeexpectancy of women at birth is 82 years in European countries, women live one third of their life in the postmenopausal state. Menopausal transition starts years before the menopause and is characterized by dramatic changes in the relationship between the hypothalamic-pituitary axis and ovary. A significant increase in gonadotrophins (follicle stimulating hormone and lutenizing hormone) is observed already five years before the menopause with peak concentrations occurring during the first three postmenopausal years (Rannevik et al. 2008) . The decreases in systemic female sex steroid (estradiol and estrone) concentrations occur much faster, within a six month period around the menopause. The changes are more dramatic in estradiol (Rannevik et al. 2008) . Both estradiol and estrone levels continue to decrease further during the first three postmenopausal years. The postmenopausal status is characterized by the presence of a very low constant systemic estradiol level. This is in contrast to the cyclic estradiol production during premenopause. Circulating estrone, synthesized from the adrenal steroids in peripheral tissue, becomes the most abundant estrogen in the circulation.
Women in the menopausal transition commonly report a variety of symptoms which are annoying and disconcerting and which may adversely affect quality of life (Greenblum et al. 2012) . HRT has been used to treat menopausal symptoms and prevent chronic conditions such as osteoporosis and related fracture. Clinical trials investigating the effectiveness of HRT in reducing the risk for sarcopenia or age-induced muscle weakness have not been performed. However, randomized controlled trials suggest that HRT may prevent strength and power decline among women at early postmenopause (Greising et al. 2009; Sipilä et al. 2001) . Preliminary data indicate that during immobilization, estrogen replacement therapy (ERT) may diminish the muscle loss among postmenopausal women (Mette Hansen, unpublished observations) . This may indicate that systemic estrogen deficiency is among the key factors for sarcopenia and age-induced muscle weakness in women.
Androgen deficiency in the ageing male Although male andropause is not as clearly defined as female menopause, it includes a gradual decrease in androgen production leading to a wide variety of symptoms occurring in men after middle age. Circulating testosterone naturally declines at a rate of approximately 1 % per year from the age of around 40 in healthy men (Gray et al. 1991; Vermeulen et al. 1996; Feldman et al. 2002) , coinciding with the onset of reductions in muscle mass. However, it is possible that in over 20 % of ageing men (Harman et al. 2001) this hormonal decline is accelerated, meaning that serum (total) testosterone can dip below the normal physiological range (i.e. below approximately 10 nmol/L) (Matsumoto 2002) . A significant number of men may therefore be eligible for testosterone replacement therapy, if both clinical symptoms and signs suggestive of androgen deficiency and decreased testosterone levels are present (American Society of Andrology (ASA) 2006).
A growing number of studies have specifically assessed whether testosterone therapy can partly reverse the ageing-related effects of reduced muscle mass and strength, in an effort to discern whether this intervention can be employed in clinical practice for this purpose. It is believed that testosterone therapy can cause increases in muscle size (Bhasin et al. 1997; Wang et al. 2000) . Some reports have also been successful in demonstrating subsequent improvements in muscle strength (Sih et al. 1997; Wang et al. 2000) . A meta-analysis of 11 randomized clinical trials in 2006 concluded that androgen treatment in elderly males does in fact promote moderate increases in strength (Ottenbacher et al. 2006) , though the results of one study of only 12 eugonadal participants drove the effect of that analysis (Ferrando et al. 2002) . Furthermore, Srinivas-Shankar and colleagues recently showed that lean body mass, lower extremity strength and physical functioning could also improve following testosterone treatment ).
Molecular mechanisms of sex steroid actions
Sex steroids are found circulating in the bloodstream in three forms. The majority (*70 %) is strongly bound to sex hormone-binding globulin (SHBG), with *20 % bound to albumin and only 2-3 % circulating freely. The free and albumin-bound forms are considered as biologically available components. Estradiol is produced from testosterone by the actions of aromatizing enzyme cytochrome P450 19A1 (Labrie et al. 1998) . The effects of estradiol on gene expression are delivered through nuclear receptors (ESR1 and ESR2). Upon activation by hormone binding, ESR1 and ESR2 form homo-or heterodimers and move to the nucleus to induce transcription of their target genes (Matthews and Gustafsson 2003) . In addition, G-protein coupled estrogen receptor (GPER) or membranebound forms of ESRs, which induce rapid signals without direct transcriptional responses, may be involved (Razandi et al. 1999; Maggiolini and Picard 2010) . ESR1 and ESR2 have been identified in human skeletal muscle (Lemoine et al. 2003; Wiik et al. 2009) and mRNA expression of GPER in murine skeletal muscle (Isensee et al. 2009 ). Information regarding GPER in human muscle was lacking before our results . In mouse muscle ESR1, and to a lesser extent also ESR2 and GPER, show responsiveness to systemic estrogen levels (Baltgalvis et al. 2010) indicating their active role in muscle adaptation to ageing.
Classically, signalling of the biologically most effective androgens, testosterone and dihydrotestosterone, is mediated by the androgen receptor (AR), which acts as a transcription factor. The AR has been shown to be present in human skeletal muscle (Kadi et al. 2000) , in particular in the satellite cell myonucleus (Sinha-Hikim et al. 2004) with abundance also at the neuromuscular junction (Monks et al. 2004) . Testosterone is an anabolic hormone, which may improve net muscle protein balance by enhancing protein synthesis and improving amino acid reutilization (Ferrando et al. 1998; Sheffield-Moore et al. 1999 ). Increases in cross-sectional area and myonuclear number associated with both type I and type II muscle fibers are partly responsible for the increase in muscle mass observed with testosterone treatment (Sinha-Hikim et al. 2002) . In addition, testosterone may promote commitment of mesenchymal pluripotent cells into the myogenic lineage (Herbst and Bhasin 2004 ) and increase satellite cell number (Sinha-Hikim et al. 2003) .
In a similar manner to the actions of estrogen, it is possible that testosterone may also act via membranebound (non-genomic) pathways, that is, independent of the intracellular AR. Since testosterone and other androgens have rapid effects (occurring within 2-3 min), testosterone potentially acts directly at the cell membrane. However, the current literature is limited to a small number of animal studies (reviewed in Dubois et al. 2012) .
In addition to steroid hormone production in the gonads and secretion into the bloodstream, formation at numerous peripheral sites may occur. Here they exhibit important paracrine functions. Recently human and rodent skeletal muscle cells have been included in the growing list of steroidogenic cells (Larionov et al. 2003; Aizawa et al. 2007) . Particularly in women after menopause, the importance of local synthesis of steroid hormones, especially estogens, is of interest. The formation of testosterone by skeletal muscle in response to exercise, and its so-called intracrine mode of action, has been reported in rats (Aizawa et al. 2007 ). Furthermore, testosterone has been measured in the skeletal muscle tissue of both men and women, though increased production by muscle cells themselves, in response to exercise, is yet to be confirmed in humans (Vingren et al. 2008) .
Study designs in investigating the association between HRT and skeletal muscle in women and men
As part of the MYOAGE project, the role of estrogens and testosterone in skeletal muscle structure, composition and function among healthy middle-aged and older women and frail older men was investigated. In addition, the underlying biological mechanisms for the observed beneficial effects of HRT on skeletal muscle of women were investigated.
Studies on estrogen containing HRT and skeletal muscle HRT related studies were heavily based on a previous randomized placebo controlled trial (RCT STUDY) suggesting that HRT and plyometric exercise training for one year have positive effects on skeletal muscle in healthy women at early postmenopause (Sipilä et al. 2001; Taaffe et al. 2005) . Women aged 50-57 years with last menses 0.5-5 years previously, folliclestimulating hormone levels greater than 30 i.u./L and no history of HRT were included in the study. In total, 80 women were randomized into four study groups; HRT, plyometric jumping exercise (Ex), ExHRT, and controls (Co). The HRT intervention included a combined estradiol (2 mg) and norethisterone acetate (1 mg) product (Kliogest2; Novo Nordic). Exercise included progressive high-impact training including bounding, drop jumping, hopping and skipping. The effects of the interventions on muscle cross-sectional area (CSA) and composition (computed tomography, CT), maximal isometric knee extension strength (KE), lower body muscle power (vertical jumping height on a contact mat, power) and running speed were assessed. In addition, needle muscle biopsies were taken from the vastus lateralis muscle.
To investigate the association between age and local steroidogenesis in the skeletal muscle, the participants of the RCT STUDY were invited to a 10 year follow-up study (postmenopausal women, not using HRT, mean age 64 ± 2 years, n = 13). In addition, randomly selected 30-35-year-old women (premenopausal women, not using hormonal contraceptives, mean age 33 ± 2 years, n = 13) were recruited .
A case-control HRT discordant study with monozygotic postmenopausal 54-62-year-old female twins (TWIN STUDY) was designed to investigate more comprehensively the molecular mechanisms underlying the effects of HRT on skeletal muscle (Ronkainen et al. 2009 ). This design controls for genetic factors and a number of shared past experiences beginning from the intrauterine environment and throughout childhood. Fifteen postmenopausal twin pairs of whom one co-twin was a current HRT user (mean duration 7 ± 4 years) and the other co-twin had never used HRT were recruited. The intra-pair differences were calculated for thigh muscle CSA and composition (CT), KE, power, plantar flexor twitch torque and maximal walking speed. In addition, needle biopsies were taken from the vastus lateralis muscle and subcutaneous abdominal fat.
To study the effect of ERT without the combined administration of synthetic gestagens (as in HRT) on the myofibrillar protein synthesis rate, a cross-sectional study (ERT-STUDY) was designed. Myofibrillar protein synthesis rate was measured by a stable isotope technique at rest and in response to resistance exercise in 10 hysterectomized/oophorectomized women (61 ± 4 years) who were using ERT (daily 2 mg oral 17b-estradiol) and in 10 age-matched postmenopausal controls (60 ± 4 years) (Hansen et al. 2012b ). Tendons and the muscle connective tissue play, besides the muscle contractile filaments, important roles during locomotion based on the dependency upon the transmission of force from muscle to the skeleton via these tissue. The content of type I collagen in tendon and ligaments is reduced in postmenopausal women (Moalli et al. 2004; Osakabe et al. 2001) , which may be related to alterations in the hormonal milieu. Based on these earlier observations, we in the ERT-STUDY compared the tendon collagen synthesis rate, the tendon characteristics and the tendon biomechanical properties between controls and long-term ERT-users (mean treatment period 16.1 ± 3.0 years) (Hansen et al. 2009 ).
Oral ERT and HRT have a marked effect on liver metabolism, for instance oral estrogen administration reduces the synthesis and secretion of IGF-I from the liver into the circulation (Bellantoni et al. 1996; Campagnoli et al. 1993) . IGF-I has a stimulating effect on the synthesis of collagen in the human muscle connective tissue (Doessing et al. 2010 ) and tendon (Hansen et al. 2012a) . Transdermal estrogen patches do not change circulating IGF-I (Pingel et al. 2012) . Therefore, to study the effect of estrogen administration on skeletal muscle independent of effects induced by changes in circulating IGF-I, a randomized controlled cross-over study was designed (TRANSDER-MAL-ERT study) (Pingel et al. 2012) . Eleven postmenopausal women (65 ± 2 years) went through a 5 day control period and a 5 day period, where two transdermal ERT patches were placed on the skin (EvorelÓ 50 lg/24 h estradiol). At day two of each period, the participants performed a strenuous onelegged resistance exercise bout to study the interaction between an enhanced estrogen level and exercise on an indirect marker of collagen synthesis (aminoterminal propeptide of type I collagen, PINP) within skeletal muscle connective tissue. The effect of exercise and transdermal ERT on collagen synthesis was measured by microdialysis technique 24 and 72 h after the exercise in both legs (Pingel et al. 2012 ).
Studies on testosterone treatment and skeletal muscle
In order to specifically assess the effects of testosterone treatment on skeletal muscle mass and strength, we undertook a small sub-study (Atkinson et al. 2010) of 30 men aged C65 years who were participating in a larger double-blind, randomized, placebo-controlled clinical trial . Participants exhibiting one or more frailty criteria (Fried et al. 2001 ) with low or borderline-low endogenous serum (B12 nmol/L) or calculated free testosterone levels (250 pmol/L) at baseline were recruited. Men in the treatment group received a transdermal hydroalcoholic testosterone gel (Testogel 1 %; Bayer Schering Plough) at a dose of 50 mg/day for 6 months. The dose was adjusted to 75 or 25 mg/day according to serum testosterone at day 10 and 3 months. Furthermore, dose adjustments were undertaken if testosterone levels remained outside the target physiological range of 18-30 nmol/L. The control group received a matched placebo gel.
Changes in parameters of muscle architecture (fascicle length, pennation angle and whole muscle thickness) were assessed by real-time B-mode ultrasonography. Such alterations have previously been detected prior to alterations in whole muscle volume (Seynnes et al. 2007) , indicating that the ultrasound method is a sensitive way to assess changes in muscle size. Plantar-flexor strength on the dominant side was measured using a portable dynamometer (Reeves et al. 2005) .
Effects of HRT on muscle mass, strength and mobility
Effects of estrogen containing HRT on muscle
Both RCT and TWIN STUDY showed that HRT is beneficial for muscle function, especially when the activity is performed with fast muscle contractions. We observe 14-16 % greater muscle power, 32 % greater plantar flexor twitch torque and 2-7 % greater running/walking speed among HRT users compared to non-users (Figs. 1b, 2) (Finni et al. 2011; Sipilä et al. 2001; Taaffe et al. 2005 ). In addition, HRT seems to have favourable effects on muscle composition and quality (Ronkainen et al. 2009; Sipilä et al. 2001; Taaffe et al. 2005) . Our studies suggest that HRT preserves muscle mass and prevents fat infiltration into the thigh muscle (Figs. 1a, 2) .
As expected, plyometric training for one year increased muscle power. In addition, a significant increase in lean body mass was observed together with increased thigh muscle attenuation coefficient compared to the Co group. Exercise in combination with HRT exceeded the benefits of Ex or HRT alone (Sipilä et al. 2001; Taaffe et al. 2005 ).
Effects of testosterone treatment on muscle A significant effect of testosterone treatment on muscle thickness was observed when compared to those in the placebo group (Fig. 3a) . No significant effect of testosterone treatment was observed on fascicle length (Fig. 3b) or pennation angle (Fig. 3c ) (Atkinson et al. 2010) . Despite a 5 % increase in plantar flexor strength in the testosterone group, and a decrease of 12 % in the placebo group, no significant effect of testosterone treatment was observed (a previously unreported finding, Fig. 3d) . Results of the main clinical trial of 274 men , of which our investigation was a sub-study, indicated that lean mass increased in the testosterone treated group (versus placebo), with a mean difference between the groups of 1.1 kg (95 % CI = 0.6-1.5; P \ 0.0001). A corresponding treatment effect of 8.6 Nm (95 % CI = 1.3-16.0; P = 0.02) in isometric knee extension peak torque was also observed.
Our ultrasound study showed that muscle thickness was preserved in men taking testosterone replacement therapy. It is reasonable to suggest that the preservation of muscle mass indicated by the results on muscle thickness were insufficient to cause an increase in pennation angle (Kawakami et al. 1993) . The transdermal testosterone preparation and dosage used in our study raised circulating testosterone levels to within the physiological range for young men. Topical gel preparations have been shown to provide a sustained release delivery system which mimics the natural hormonal profile for healthy men which is perhaps of use in treating those where avoiding the risk of adverse events associated with supraphysiological levels (Bhasin et al. 2005 ) is paramount. This is especially desirable in the elderly, who may already be at risk of developing cardiovascular complications (Basaria et al. 2010) . Despite this, high-dose regimens which raise circulating testosterone levels into the supraphysiological range have been shown to elicit significant gains in muscle mass in both young (Bhasin et al. 1996) and older (Bhasin et al. 2005) men. It is possible that the comparatively low dose administered in our study may indeed preserve a degree of muscle mass, but may not represent a sufficiently potent stimulus to cause overt hypertrophy. Any benefits associated with testosterone therapy must therefore be carefully weighed against the potential disadvantages, especially in the older population.
This work contributes to the body of knowledge supporting the case that physiological testosterone replacement can cause modest increases in muscle mass. Whether this is translated into sizeable gains in muscle strength requires further study on a larger scale.
Molecular mechanisms underlying estrogen containing HRT induced responses in skeletal muscle of postmenopausal women
We showed that HRT either preserves or improves skeletal muscle composition and function among postmenopausal women. In order to investigate the biological mechanisms underlying these observations, we performed a number of genetic and molecular biology analyses from muscle and fat tissue as well as from the blood samples collected from our participants. In the following paragraphs and in the Fig. 4 we will summarize the findings published prior to November 2012.
Genome-wide transcription analysis DNA microarrays can be used to comprehensively explore the genome-wide activities within a tissue. Our pioneering RCT STUDY showed that at the early stage of postmenopause, skeletal muscle transcription changes notably (4195 transcripts) and that a yearlong HRT effectively reduces these changes (97 transcripts) (Pöllänen et al. 2007 ). The samples collected in the TWIN STUDY were used to identify differences in muscle transcriptome due to long-term HRT discordance (Ronkainen et al. 2010) . We showed that HRT use was associated with higher expression of 22 genes and lower expression of 33 genes. Of these, genes related to organization of the cytoskeleton, cellenvironment interactions, energy metabolism and responses to nutrition explained a substantial fraction of the observed variation in muscle composition (18-26 %) and power (19-20 %). Although energy metabolism was affected through downregulation of the transcripts related to succinate dehydrogenase complex in mitochondria, no differences were observed in number of mitochondria or oxidative capacity per muscle sample cross-section.
IGF-1 signalling
Muscle tissue is regulated by many overlapping and interacting signalling cascades. IGF-1/PI3K/AKT pathway activates protein synthesis and inhibits degradation thereby controlling the net balance of muscle protein turnover. The IGF-1 pathway can be activated by muscle contraction and by endo-or paracrine stimulus induced by insulin, IGF-1 (Rommel et al. 2001; Bolster et al. 2004) or sex steroids (Pöllänen et al. 2010b) . We showed that the skeletal muscle of postmenopausal women not on HRT had significantly lower expression of IGF-1 compared to the premenopausal women (28 % for IGF-1Ea and 40 % for IGF1Ec, i.e., mechano growth factor, MGF). In addition, twin sisters using HRT had 28 % higher expression of IGF-receptor than their co-twins not on HRT (Ahtiainen et al. 2012b ).
More detailed information about the effects of HRT on the IGF-1 signalling cascade was gained from the microarray data of the RCT STUDY. HRT for one year increased significantly the intramuscular expression of IGF-1 gene (13 %) compared to the Co group (-16 %) Fig. 4 Summary of the suggested molecular pathways via which estrogen based hormone replacement therapy effects on skeletal muscle function, composition and quality in postmenopausal women signalling pathway, HRT downregulated AKT1, upregulated AR and IGF-1Ec (HRT 58 %, Co -31 %) and maintained FOXO3 and mTOR expressions compared to the Co. Furthermore, the change in the expression of IGF-1Ec was positively associated with the size of the thigh muscle measured at post-intervention (Pöllänen et al. 2010b ).
Skeletal muscle steroidogenesis in women
The gene expression of six enzymes needed for local synthesis of testosterone, dihydrotestosterone and estradiol was studied in muscle samples from preand postmenopausal women not on any hormone therapy. In addition, the expression of steroid hormone receptors ESR1, GPER and AR, was studied. The expression levels of steroidogenic enzymes were found to be relatively low, although showing a trend of being higher in the samples of postmenopausal women compared to premenopausal, except for 5a-reductase 1. A similar trend was found to ESR1, an opposite trend for GPER while AR expression did not differ between pre-and postmenopausal women. Moreover, postmenopausal women had higher concentrations of testosterone and estradiol in the muscle tissue than the premenopausal women. The higher amount of steroidogenic enzymes within muscle tissue indicates that muscles of postmenopausal women are able to compensate for low levels of systemic hormones by enhancing the local hormone synthesis. The higher amount of fat infiltration found in postmenopausal compared to premenopausal women's muscle may partly explain this finding.
Inflammatory factors-cross-talk between IL6 and IGF-1 pathways
The low-grade inflammatory status is associated with adiposity and muscle weakness (Ferrucci et al. 2002; Franceschi et al. 2000) . Ex vivo studies have shown the association of estrogen deficiency with the increased expression and secretion of interleukin 1 (IL-1), interleukin 6 (IL-6) and tumor necrosis factora (TNF-a), as well as the association of estrogen supplementation with decreased cytokine levels (Pfeilschifter et al. 2002) . Since our RCT STUDY showed that HRT enhances IGF-1 signalling, we wanted to study the interaction between IL-6 and IGF-1 pathways and their association with HRT in more detail (Ahtiainen et al. 2012b ). We determined IL-6 and its receptors in circulation and their transcripts in leukocytes, muscle and adipose tissue collected from the TWIN STUDY participants and premenopausal women. The circulating levels of IL-6 receptors, sIL-6R and sgp130, were significantly higher in postmenopausal women than in premenopausal women. Postmenopausal HRT-using twins had lower circulating receptor levels than their non-using co-twins. Differences in serum levels of IL-6 or IL-6R and gp130A were abolished after adjusting for body fat. The transcript analyses emphasized major contribution by adipose tissue on systemic levels of IL-6, sgp130 and sIL6R, while the contribution by muscle itself was low, both at pre-and postmenopausal age. In line with this, no significant effect was observed in the TRANSDERMAL-ERT-STUDY on systemic level of IL-6 and peripheral concentration of IL-6 within the skeletal muscle during a very short-term treatment period (5 days) (Pingel et al. 2012) .
A strong negative association (r = -0.71) was found between serum IGF-1 and serum IL6-R in HRTusing postmenopausal women, but not in their nonusing co-twins. Proinflammatory cytokines are known to act as negative regulators of IGF-1. They control the secretion of IGF-1, decrease IGF-1 sensitivity by increasing the production of IGF binding proteins, and they can cause IGF-1 resistance. To summarize, postmenopausal inflammatory status may cause IGF-1 resistance in skeletal muscle, which HRT potentially resists by increasing the amount of IGF-1R and by stimulating the post-receptor signalling (Ahtiainen et al. 2012b ). However, we cannot distinguish the direct effects of HRT on the IGF-1 pathway from possible indirect effects via IL-6 signalling. Altogether, these data suggest that HRT has positive anti-catabolic effects on ageing skeletal muscle of women.
Adipokines and insulin sensitivity
Adipokines, adiponectin and leptin, act in the control of energy expenditure, lipid and carbohydrate metabolism as well as in inflammatory responses (Carbone et al. 2012) . The adipokine MCP-1 (monocyte chemotactic protein-1), also secreted by adipose tissue, acts not only as a primary chemo attractant at sites of inflammation, but also plays a critical role in insulin resistance and cardiovascular disease (Niu and Kolattukudy 2009) . Our RCT and TWIN STUDIES showed a healthier amount and distribution of body fat in HRT-using than non-using postmenopausal women, potentially affecting the status of the adipokines. Consequently, TWIN STUDY samples were used to determine the insulin sensitivity in terms of fasting glucose, glycated hemoglobin (HbA1c) and insulin well as the amount of the adipokines MCP-1, adiponectin and leptin in circulation and their transcripts in muscle, adipose tissue and leukocytes (Ahtiainen et al. 2012a) . The most notable finding was a 15 % lower level of serum MCP-1 in HRT using twins compared to their non-using co-twins. Also circulating leptin levels tended to be lower in HRT-users. Both differences were abolished after adjustment for body fat. Contrary to this, body fat adjustment of serum adiponectin increased the difference between HRTusers and non-users, in favour of higher adiponectin in HRT-using co-twins. Serum fasting glucose levels and HbA1c, as a systemic indicator of long-term glucose exposure, were slightly lower in HRT-using than in non-using co-twins, while insulin levels did not differ. Altogether, these results suggest that the healthier body composition of long-term HRT-users is associated with better adipokine profile with concomitant signs of improved insulin sensitivity.
Skeletal muscle protein synthesis rates
Results from the ERT-STUDY showed a significant increase in myofibrillar fractional protein synthesis rate in response to resistance exercise in the ERTusers, whereas no difference between the exercisedleg and contra-lateral leg was observed in controls (Hansen et al. 2012b) . The data support a synergistic anabolic effect by estrogen administration combined with strenuous training, as observed by Sipilä et al. (2001) and Taaffe et al. (2005) .
If muscle fibre area is enhanced by ERT and training a remodelling of the surrounding muscle connective tissue is required. In line with this, the TRANSDERMAL-ERT-STUDY showed that ERT combined with resistance exercise enhanced the synthesis of collagen (PINP) within muscle connective tissue (interaction p \ 0.01) (Pingel et al. 2012) . Furthermore, in the ERT-STUDY a higher tendon collagen synthesis rate, changes in the fibril characteristics and lower relative tendon stiffness were observed in the ERT-users compared to controls, and a positive correlation between tendon collagen synthesis rate and the circulating estradiol was observed among ERT-users (Hansen et al. 2009 ). In addition to this, Cook et al. (2007) have reportedbased on cross-sectional data that HRT ameliorate the abnormality in the Achilles tendon diameter in active postmenopausal women. In summary, estrogen may not only be important for maintaining muscle mass, but influences the protein turnover, tissue morphology and the mechanical properties of tendon and muscle connective tissue, which are essential for an optimal muscle function.
Physical exercise vs HRT induced transcriptional responses in skeletal muscle
As shown in previous sections, both physical exercise and HRT have been shown to possess beneficial effects on muscle function, composition and quality in postmenopausal women. It is possible that both interventions induce similar changes in muscle transcriptome. It is as likely that they use completely different signalling routes. In order to clarify this issue, the genome-wide transcription study was made using baseline and post-intervention muscle samples from HRT, Ex and Co women of the RCT STUDY (Pöllänen et al. 2010a ). Many of the age-related transcriptomic changes were reduced by HRT which significantly affected the expression of 54 genes. Of them, many were related to energy metabolism or involved in other mitochondrial functions including genes encoding mitochondrial ribosomal proteins, mitochondrial chaperons and proteins needed in oxidative phosphorylation, citric acid cycle and fatty acid oxidation. The plyometric jumping exercise significantly changed the expression of 510 genes. Of them most notable GO annotations included biological processes energy metabolism and response to contraction. However, the clustering analysis of significantly affected genes also revealed a punch of genes similarly affected by HRT and Ex. Here again, the energy metabolism was among the enriched GO categories together with calcium signalling. In addition to specific and shared effects of HRT and Ex, we found 363 genes which significantly changed their expression level during yearlong intervention without HRT or exercise. From these ''ageing'' genes, 40 were unknown without GO or KEGG classification while the rest were related to common terms: energy metabolism, oxidation-reduction reactions, extracellular matrix and regulation of muscle development and contraction. In light of our microarray results, it seems clear that regulation of muscle energy metabolism at transcriptional level is among the key processes affecting muscle function and composition during ageing. Furthermore, both HRT and plyometric exercise are able to improve energy metabolism related signalling in skeletal muscle of postmenopausal women.
Conclusions and future perspectives
The ageing process is influenced by genes, but not fully defined by them (see e.g. Rattan 2006 Rattan , 2008 . More so, ageing is caused by the accumulation of a wide variety of faults in gene products leading to dysfunctional cell compartments and cells in different tissues all over the human body. Ageing-related deterioration in endocrine functions has wide ranging effects on different organs and body systems, one of them being skeletal muscle. According to the results obtained in the MYOAGE-project, women after menopause are subjected to decrements in muscle function and quality. Use of estrogen-containing HRT, in turn, improves muscle function, maintains muscle mass and prevents fat infiltration into the muscle compartment. Our genome-wide studies showed that the muscle transcriptome of women changes remarkably during first postmenopausal years. These changes can be affected by external stimuli such as HRT or exercise. These treatments can thus be considered as counteractive treatments to ageing-related changes in muscle phenotype. In particular, gene expression related to many functional categories important for the plasticity of skeletal muscle were affected, including proteolytic processes, mitochondrial functions, energy metabolism, Ca 2? -signalling and response to external stimulus-related genes. Furthermore, HRT affected the IGF-1 and IL-6 signalling as well as adipokines, which are potential pathways regulating muscle mass and function, and improved insulin sensitivity.
Results pertaining to the effect of testosterone indicate, to some degree, that replacement of this hormone to normal physiological levels may have positive effects on skeletal muscle, if only to preserve muscle tissue and offset age-related muscle loss, rather than cause significant gains. Physiological testosterone replacement could therefore be of benefit in prefrail community-dwelling older men whose circulating testosterone levels have fallen below the lower physiological limit, who maintain a reasonable level of mobility, but who may be at risk of further decline if left untreated. Such treatment may be viewed as a preventative strategy, to avoid the negative effects of advanced muscle wasting. However, to examine the impact of longer-term treatment, further longitudinal studies over a number of years are required. Moreover, stronger anabolic stimuli may be warranted in individuals where muscle atrophy is a major cause for concern. However, since supraphysiological doses of testosterone have been associated with a range of adverse effects, the future of androgen therapies may depend heavily on the development of selective androgen receptor modulators (SARMs). SARMs, similar in principle to androgenic-anabolic steroids, aim to maximise the positive anabolic effects of androgens, whilst minimizing negative effects such as those previously outlined (Mohler et al. 2009 ). By selectively targeting the androgen receptor in specific tissues such as muscle, SARMs may be refined to elicit anabolic effects, whilst avoiding unwanted effects in other tissues. The development of such molecules would enable treatment of patients who are at greater risk of adverse effects occurring.
Furthermore, the effect of androgens on skeletal muscle mass may be enhanced by a combination of pharmacological treatment and specific exercise regimes. In particular, resistance training with concomitant androgen therapy might offer the greatest benefits. It is currently unknown whether treatment with testosterone can provide a boost to enhance physical capacity in frail older individuals with impaired mobility or chronic disease.
The MYOAGE project has addressed important topics, which have also been presented by FUTUR-AGE-a roadmap for European ageing research. The results obtained aid progression of ageing research especially by providing new insight on sex hormones, i.e., nuclear receptor-delivered effects on mitochondrial dysfunction, protein damage and maintenance, inflammation, metabolic factors and their roles in combating sarcopenia. Aging is not controlled by a single mechanism only but a combination of processes occurring in different tissues and organ systems (Rattan 2012 ). More research is needed to transfer genome-wide transcriptomic studies to proteome level. In addition, more comprehensive studies including several tissues and combining different omics data (genomic, transcriptomic, proteomic, metabolomic, epigenetics etc.) should be performed to define biomarkers of ageing muscle and individual variations in those biomarkers. Animal models provide important opportunities to overcome study design restrictions due to the slow ageing of humans. However, eventually studies conducted on animals should be transferred to the human context, which demands longitudinal follow-up studies, e.g., investigating the effects of menopause on body and muscle composition, and ideally expanding over the scope of multiple year funding periods and co-operation between policy makers, clinicians and researchers and research organizations in different fields of ageing research. Promising research approaches likely to provide important novel means to combat sarcopenia and muscle weakness include studies on microRNArelated posttranscriptional control, regulation and functions of peripheral steroid hormone synthesis, cross-talk between nuclear receptor and metabolic signalling pathways and hormonal regulation of energy metabolism.
